The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
TAGRISSO (AstraZeneca Pty Ltd)
Product name
TAGRISSO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
226 (255 working days)
Active ingredients
osimertinib mesilate
Registration type
EOI
Indication
TAGRISSO is indicated in combination with:
- pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 L858R mutations.